RT Journal Article
SR Electronic
T1 Association between cardiometabolic phenotypes with atherogenic index of plasma: a cross-sectional study from the Azar Cohort Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.29.24311169
DO 10.1101/2024.07.29.24311169
A1 Soheilifard, Shireen
A1 Mahdavi, Reza
A1 Faramarzi, Elnaz
YR 2024
UL http://medrxiv.org/content/early/2024/07/30/2024.07.29.24311169.abstract
AB Background This study was conducted to determine the relationship between cardiometabolic phenotypes and atherogenic index of plasma in the Azar cohort population.Methods This cross-sectional study included 9,515 participants aged 35 to 55, using data from the Azar Cohort Study. Metabolic syndrome was defined based on ATP III criteria. Participants were then classified into four cardiometabolic phenotypes by considering BMI and metabolic syndrome components: metabolically healthy normal weight (MHNW, BMI <25 kg/m²), metabolically unhealthy normal weight (MUHNW, BMI <25 kg/m²), metabolically healthy obese (MHO, BMI ≥25 kg/m²), and metabolically unhealthy obese (MUHO, BMI ≥25 kg/m²). AIP was calculated.Result Among the subjects, 4,801 (50.5%) were metabolically healthy obese (MHO) and 2,680 (28.2%) were metabolically unhealthy obese (MUHO). High-risk AIP levels (>0.21) differed significantly across cardiometabolic phenotypes, with MUHNW (79.6%) and MUHO (64.6%) showing the highest proportions compared to MHNW (13.5%) and MHO (18.6%). After adjusting for confounders, multinomial logistic regression analysis showed individuals in the third tertile of AIP were 103.46 times more likely to be MUHNW (OR = 103.46, 95% CI: 52.82– 202.64), 55.77 times more likely to be MUHO (OR = 55.77, 95% CI: 45.65–68.12), and 2.22 times more likely to be MHO (OR = 2.22, 95% CI: 1.91–2.64) compared to the MHNW phenotype (p < 0.001 for all).Conclusion The study demonstrates significant variation in high-risk AIP levels across cardiometabolic phenotypes, emphasizing the need for detailed metabolic health assessments beyond BMI to better predict cardiovascular risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the liver and gastrointestinal diseases research center (Grant No. 700/108 on 14 March 2016), Tabriz University of Medical Sciences. The funder had no role on the study design, data analysis, interpreting and writing the manuscript in this study. The Iranian Ministry of Health and Medical Education has contributed to the funding used in the PERSIAN Cohort through Grant no.700/534. The funder had no role on the study design, data analysis, interpreting and writing the manuscript in this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethical Board of the Research Council of Tabriz University of Medical Sciences (No.IR.TBZMED.REC.1402.428).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available from [Vice Chancellor for Research] but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of [Vice Chancellor for Research]AIPAtherogenic index of plasmaMHNWMetabolically healthy normal weightMUHNWMetabolically unhealthy normal weightMHOMetabolically healthy obeseMUHOMetabolically unhealthy obeseWSIWealth Score IndexMCAMultiple correspondence analysisMETsMetabolic equivalentsTGTriglycerideHDL-CHigh-density lipoprotein cholesterolLDL-CLow-density lipoprotein cholesterolFBGFasting blood glucoseWCWeist circumferenceHCHip circumferenceBMIBody mass indexSBPSystolic Blood PressureDBPDiastolic Blood Pressure